Neuroinflammation, the persistent activation of the brain’s immune system, is increasingly recognized as a common driver of neurological damage. It appears in conditions ranging from neurodegenerative diseases to traumatic injury and viral infections of the central nervous system. A study by Xu, Pan, Li and colleagues, published in Nature Communications, reports that engineered nanovesicles designed to target METTL3, a key molecular “writer” of the RNA modification m6A, can reduce neuroinflammation in laboratory systems and animal models. The findings point to a potential strategy for controlling harmful immune activity without broadly suppressing the brain’s protective defenses.
The research focuses on N6-methyladenosine, commonly called m6A, the most abundant internal chemical modification found on messenger RNA in mammalian cells. Messenger RNA carries genetic instructions from DNA to the cellular machinery that produces proteins. By adding or removing m6A marks, cells can influence how long an RNA molecule survives, how efficiently it is translated into protein, and how it is processed. These changes help cells respond rapidly to stress, infection, and inflammation. However, when m6A regulation becomes unbalanced, the same system may contribute to persistent disease-related signaling.
METTL3 is one of the central enzymes responsible for installing m6A marks on RNA. It works as part of a larger molecular complex, often referred to as the m6A writer machinery. Previous studies have connected abnormal METTL3 activity with immune-cell activation, cancer biology, and inflammatory responses in the nervous system. Because METTL3 can influence the expression of numerous genes at once, directly altering its activity could potentially reshape entire inflammatory programs. The challenge is delivering such an intervention to the right tissues while avoiding unwanted effects elsewhere in the body.
To address that challenge, the investigators used engineered nanovesicles. These nanoscale particles are enclosed by lipid membranes and can be designed to transport biological or chemical cargo into target cells. Nanovesicles are attractive for neurological applications because their size and surface properties can be adjusted to influence tissue distribution, cellular uptake, and interactions with biological barriers. In this study, the vesicles were configured to target the METTL3 pathway, allowing the researchers to test whether a localized molecular intervention could dampen inflammatory signaling more selectively than a conventional systemic drug.
The researchers examined the effects of the METTL3-targeting nanovesicles in vitro, using cultured cells to observe how the treatment affected inflammatory responses under controlled conditions. Such experiments can reveal whether the engineered particles enter cells, whether they alter the intended RNA-regulatory pathway, and whether inflammatory molecules decline after treatment. The study’s central observation was that targeting METTL3 with the engineered vesicles reduced indicators of neuroinflammation in these laboratory systems. This suggests that the RNA-modification machinery is not merely associated with inflammation but may be therapeutically actionable.
The work also extended beyond cell cultures into in vivo models, an important step because the brain’s immune environment is shaped by complex interactions among neurons, astrocytes, microglia, blood vessels, and infiltrating immune cells. Microglia, the resident immune cells of the central nervous system, can shift between protective and damaging states depending on the signals they receive. Excessive or prolonged activation can release cytokines, chemokines, and other mediators that disrupt neuronal function and damage surrounding tissue. According to the report, the nanovesicle-based METTL3 intervention reduced neuroinflammatory responses in living organisms, indicating that the platform can function within a more complex biological environment.
The findings are particularly relevant to emerging research on viral neuroinflammation. Some viruses that infect or affect the nervous system can trigger immune reactions that continue after the initial pathogen burden has fallen. In these situations, tissue damage may result not only from viral replication but also from an immune response that becomes poorly controlled. RNA modifications such as m6A are already known to influence interactions between host cells and viruses, including viral RNA stability, replication, and immune recognition. A delivery system that adjusts METTL3 activity could therefore become useful for investigating how inflammatory responses develop during viral or post-viral neurological disease, although the present study does not establish a treatment for any specific infection.
The approach remains experimental, and several questions will need to be answered before it can move toward clinical testing. Researchers must determine how precisely the nanovesicles distribute through the brain, how long their effects last, and whether repeated administration causes toxicity or immune reactions. It will also be necessary to define which RNA transcripts are altered after METTL3 targeting and to distinguish beneficial suppression of inflammation from interference with normal immune surveillance. Because m6A regulation affects many cellular processes, dose, timing, and tissue specificity will be critical factors in future development.
Even with these limitations, the study highlights a convergence of two rapidly advancing fields: epitranscriptomics, which examines chemical marks on RNA, and nanomedicine, which seeks to deliver therapies with greater precision. By combining a molecular target involved in gene regulation with a vehicle engineered for cellular delivery, the researchers offer a framework for treating neuroinflammation at the level of its regulatory circuitry. The results do not yet demonstrate effectiveness in human disease, but they provide evidence that METTL3-directed nanovesicles could become a platform for future investigations into inflammatory neurological disorders, including conditions in which viral infection and immune-mediated damage overlap.
Subject of Research: Engineered nanovesicles targeting the m6A writer METTL3 to reduce neuroinflammation in vitro and in vivo.
Article Title: Targeting m6A writer METTL3 with engineered nanovesicles reduces neuroinflammation in vitro and in vivo.
Article References: Xu, L., Pan, Y., Li, G. et al. Targeting m6A writer METTL3 with engineered nanovesicles reduces neuroinflammation in vitro and in vivo. Nature Communications (2026). https://doi.org/10.1038/s41467-026-75862-4
Image Credits: AI Generated
DOI: 10.1038/s41467-026-75862-4
Keywords: Neuroinflammation, METTL3, m6A RNA modification, engineered nanovesicles, epitranscriptomics, nanomedicine, neuroimmunology, viral neuroinflammation
Tags: engineered nanovesicles for RNA modification targetinginnovative treatments for CNS infections and traumaMETTL3 enzyme and m6A RNA methylationmolecular strategies to control neuroinflammationnanotechnology-based neuroimmune modulationnanovesicle delivery systems in neurobiologyneurodegenerative disease mechanismsneuroinflammationRNA methylation in brain immune responsesRNA modification enzymes in neurological disordersrole of m6A in neural injurytargeted therapy for neuroinflammation
